Source: Davit Kirakosyan
Walgreens Boots Alliance Exceeds Q4 2024 Expectations
On Tuesday, shares of the multinational pharmacy and retail company, Walgreens Boots Alliance (NASDAQ:WBA), soared by more than 12% intra-day. This surge was driven by the company’s fiscal Q4 2024 results, which exceeded Wall Street predictions. The company reported earnings per share (EPS) of $0.39, surpassing the expected $0.36, and revenue of $37.55 billion, outpacing the estimated $35.75 billion. This significant beat is a testament to the company’s resilience and strategic initiatives amidst a challenging retail environment.
Strong Performance in International and U.S. Retail Pharmacy Sales
Walgreens’ Q4 performance was buoyed by robust growth in both international and U.S. retail pharmacy sales. International sales experienced a 3.2% year-over-year rise to reach $5.97 billion, comfortably beating projections of $5.84 billion. In the U.S., Retail Pharmacy sales climbed 6.5% to $29.47 billion, surpassing the expected $27.48 billion, showcasing the company’s strong positioning in the domestic market. However, U.S. Healthcare sales, though growing by 7.2% to reach $2.11 billion, fell slightly short of the forecasted $2.15 billion.
Gross Margin and Fiscal 2025 Forecast
Despite the strong sales figures, Walgreens reported a dip in its adjusted gross margin. The margin fell to 16.9%, down from 18.6% in the previous year, and short of the expected 17.6%. This indicates potential challenges in managing costs or pricing pressures that could be impacting profitability. However, looking ahead to fiscal 2025, the company’s forecast appears optimistic. Walgreens anticipates EPS to be between $1.40 and $1.80, with revenue projected at $147 billion to $151 billion. Both these figures are slightly above Street expectations. Furthermore, the company anticipates an adjusted operating income of $1.6 billion to $2.0 billion, which aligns with the $1.89 billion consensus among analysts.
Strategic Steps to Address Ongoing Challenges
The retail giant also announced plans to close 1,200 stores over the next three years, a strategic decision taken under the leadership of new CEO Tim Wentworth. This move comes as the company navigates through a challenging market characterized by weak consumer spending and declining drug reimbursement rates. By reducing its physical footprint, Walgreens aims to optimize its operations, improve efficiency, and enhance its focus on e-commerce and digital health solutions.
Conclusion
Despite the challenges, Walgreens Boots Alliance’s better-than-expected Q4 results demonstrate the company’s ability to adapt and thrive in a rapidly changing retail landscape. The company’s strong performance in international and U.S. retail pharmacy sales, along with an optimistic fiscal 2025 forecast, suggests a promising future. However, the dip in gross margin indicates potential hurdles the company needs to overcome. The strategic decision to close stores, under the new leadership, indicates a willingness to adapt to changing market conditions and consumer behavior. While the journey ahead may be challenging, Walgreens appears to be taking the necessary steps to ensure its long-term success and growth.